

# Paul Zeun

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/703621/publications.pdf>

Version: 2024-02-01

168  
papers

10,888  
citations

61984

43  
h-index

37204

96  
g-index

173  
all docs

173  
docs citations

173  
times ranked

9667  
citing authors

#	ARTICLE	IF	CITATIONS
1	Huntington disease. Nature Reviews Disease Primers, 2015, 1, 15005.	30.5	1,031
2	Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology, 2014, 10, 204-216.	10.1	873
3	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurology, The, 2009, 8, 791-801.	10.2	856
4	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurology, The, 2013, 12, 637-649.	10.2	704
5	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurology, The, 2011, 10, 31-42.	10.2	530
6	Targeting Huntingtin Expression in Patients with Huntington's Disease. New England Journal of Medicine, 2019, 380, 2307-2316.	27.0	493
7	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurology, The, 2012, 11, 42-53.	10.2	479
8	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurology, The, 2017, 16, 601-609.	10.2	272
9	Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurology, The, 2017, 16, 837-847.	10.2	233
10	<sc>N</sc>omenclature of genetic movement disorders: <sc>R</sc>ecommendations of the international <sc>P</sc>arkinson and movement disorder society task force. Movement Disorders, 2016, 31, 436-457.	3.9	228
11	Huntingtin Lowering Strategies for Disease Modification in Huntington's Disease. Neuron, 2019, 101, 801-819.	8.1	202
12	DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. Annals of Neurology, 2016, 79, 983-990.	5.3	183
13	Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Human Molecular Genetics, 2000, 9, 2683-2689.	2.9	182
14	The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients. Scientific Reports, 2017, 7, 1307.	3.3	150
15	Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. Neurobiology of Disease, 2015, 83, 115-121.	4.4	133
16	Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. PLOS Currents, 2010, 2, RRN1184.	1.4	124
17	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine, 2015, 2, 1420-1429.	6.1	122
18	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurology, The, 2020, 19, 502-512.	10.2	122

#	ARTICLE	IF	CITATIONS
19	KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4676-E4685.	7.1	119
20	A SNP in the HTT promoter alters NF- $\kappa$ B binding and is a bidirectional genetic modifier of Huntington disease. Nature Neuroscience, 2015, 18, 807-816.	14.8	113
21	Clinical Features of Huntington's Disease. Advances in Experimental Medicine and Biology, 2018, 1049, 1-28.	1.6	109
22	A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes. EBioMedicine, 2019, 48, 568-580.	6.1	104
23	Emotion recognition in Huntington's disease: A systematic review. Neuroscience and Biobehavioral Reviews, 2012, 36, 237-253.	6.1	101
24	FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat. Human Molecular Genetics, 2019, 28, 650-661.	2.9	99
25	Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology, 2017, 89, 2495-2502.	1.1	97
26	Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. Brain, 2015, 138, 3016-3029.	7.6	90
27	Brain Regions Showing White Matter Loss in Huntington's Disease Are Enriched for Synaptic and Metabolic Genes. Biological Psychiatry, 2018, 83, 456-465.	1.3	79
28	Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 147, 255-278.	1.8	79
29	A biological classification of Huntington's disease: the Integrated Staging System. Lancet Neurology, The, 2022, 21, 632-644.	10.2	78
30	DNA repair in the trinucleotide repeat disorders. Lancet Neurology, The, 2017, 16, 88-96.	10.2	75
31	Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. Movement Disorders Clinical Practice, 2019, 6, 541-546.	1.5	67
32	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology, 2018, 90, e717-e723.	1.1	65
33	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. Science Translational Medicine, 2020, 12, .	12.4	64
34	Operationalizing compensation over time in neurodegenerative disease. Brain, 2017, 140, 1158-1165.	7.6	62
35	Antisense oligonucleotides for neurodegeneration. Science, 2020, 367, 1428-1429.	12.6	62
36	Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. Journal of Neurochemistry, 2016, 139, 22-25.	3.9	58

#	ARTICLE	IF	CITATIONS
37	Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease. PLoS ONE, 2016, 11, e0163479.	2.5	58
38	White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression. Cortex, 2014, 52, 98-112.	2.4	57
39	The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. Neuropsychologia, 2015, 79, 138-146.	1.6	56
40	The human motor cortex microcircuit: insights for neurodegenerative disease. Nature Reviews Neuroscience, 2020, 21, 401-415.	10.2	56
41	In vivo characterization of white matter pathology in premanifest huntington's disease. Annals of Neurology, 2018, 84, 497-504.	5.3	53
42	Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin-proteasome system. Acta Neuropathologica, 2016, 131, 411-425.	7.7	51
43	Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiology of Disease, 2015, 73, 388-398.	4.4	50
44	Incidence of adult Huntington's disease in the UK: a UK-based primary care study and a systematic review. BMJ Open, 2016, 6, e009070.	1.9	49
45	RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Human Molecular Genetics, 2016, 25, ddw142.	2.9	47
46	Gene suppression approaches to neurodegeneration. Alzheimer's Research and Therapy, 2017, 9, 82.	6.2	46
47	The Dementias Platform UK (DPUK) Data Portal. European Journal of Epidemiology, 2020, 35, 601-611.	5.7	45
48	Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease. Journal of the International Neuropsychological Society, 2016, 22, 595-608.	1.8	44
49	Association of CAG Repeats With Long-term Progression in Huntington Disease. JAMA Neurology, 2019, 76, 1375.	9.0	44
50	Quality of Life in Huntington's Disease: A Comparative Study Investigating the Impact for those with Pre-Manifest and Early Manifest Disease, and their Partners. Journal of Huntington's Disease, 2013, 2, 159-175.	1.9	43
51	Validation of a prognostic index for Huntington's disease. Movement Disorders, 2017, 32, 256-263.	3.9	42
52	Correction of inter-scanner and within-subject variance in structural MRI based automated diagnosing. NeuroImage, 2014, 98, 405-415.	4.2	40
53	Polyglutamine diseases. Current Opinion in Neurobiology, 2022, 72, 39-47.	4.2	40
54	A Computational Cognitive Biomarker for Early-Stage Huntington's Disease. PLoS ONE, 2016, 11, e0148409.	2.5	40

#	ARTICLE	IF	CITATIONS
55	Disruption of immune cell function by mutant huntingtin in Huntington's disease pathogenesis. <i>Current Opinion in Pharmacology</i> , 2016, 26, 33-38.	3.5	39
56	Task-Specific Training in Huntington Disease: A Randomized Controlled Feasibility Trial. <i>Physical Therapy</i> , 2014, 94, 1555-1568.	2.4	37
57	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. <i>Journal of the Neurological Sciences</i> , 2016, 368, 243-248.	0.6	37
58	In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington's disease. <i>Scientific Reports</i> , 2018, 8, 11447.	3.3	36
59	Subcellular Localization And Formation Of Huntingtin Aggregates Correlates With Symptom Onset And Progression In A Huntington's Disease Model. <i>Brain Communications</i> , 2020, 2, fcaa066.	3.3	34
60	Neuropsychiatry and White Matter Microstructure in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2015, 4, 239-249.	1.9	33
61	Prion degradation pathways: Potential for therapeutic intervention. <i>Molecular and Cellular Neurosciences</i> , 2015, 66, 12-20.	2.2	33
62	Stimulating neural plasticity with real-time fMRI neurofeedback in Huntington's disease: A proof of concept study. <i>Human Brain Mapping</i> , 2018, 39, 1339-1353.	3.6	33
63	Testing a longitudinal compensation model in premanifest Huntington's disease. <i>Brain</i> , 2018, 141, 2156-2166.	7.6	33
64	Overlap between age-at-onset and disease-progression determinants in Huntington disease. <i>Neurology</i> , 2018, 90, e2099-e2106.	1.1	32
65	Dynamics of Cortical Degeneration Over a Decade in Huntington's Disease. <i>Biological Psychiatry</i> , 2021, 89, 807-816.	1.3	32
66	FAN1 controls mismatch repair complex assembly via MLH1 retention to stabilize CAG repeat expansion in Huntington's disease. <i>Cell Reports</i> , 2021, 36, 109649.	6.4	32
67	Longitudinal Diffusion Tensor Imaging Shows Progressive Changes in White Matter in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2015, 4, 333-346.	1.9	31
68	George Huntington: a legacy of inquiry, empathy and hope. <i>Brain</i> , 2016, 139, 2326-2333.	7.6	31
69	Recommendations for the Use of Automated Gray Matter Segmentation Tools: Evidence from Huntington's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 519.	2.4	31
70	Interregional compensatory mechanisms of motor functioning in progressing preclinical neurodegeneration. <i>NeuroImage</i> , 2013, 75, 146-154.	4.2	30
71	Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. <i>Journal of Neurochemistry</i> , 2016, 137, 782-794.	3.9	30
72	Corpus Callosal Atrophy in Premanifest and Early Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2013, 2, 517-526.	1.9	29

#	ARTICLE	IF	CITATIONS
73	Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease. <i>Human Brain Mapping</i> , 2017, 38, 2819-2829.	3.6	28
74	Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice. <i>Scientific Reports</i> , 2017, 7, 14275.	3.3	27
75	Predicting clinical diagnosis in Huntington's disease: An imaging polymarker. <i>Annals of Neurology</i> , 2018, 83, 532-543.	5.3	26
76	Fronto-striatal circuits for cognitive flexibility in far from onset Huntington's disease: evidence from the Young Adult Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 143-149.	1.9	26
77	Genetic testing in dementia – utility and clinical strategies. <i>Nature Reviews Neurology</i> , 2021, 17, 23-36.	10.1	26
78	Human Huntington's disease pluripotent stem cell-derived microglia develop normally but are abnormally hyper-reactive and release elevated levels of reactive oxygen species. <i>Journal of Neuroinflammation</i> , 2021, 18, 94.	7.2	26
79	A Critical Evaluation of Inflammatory Markers in Huntington's Disease Plasma. <i>Journal of Huntington's Disease</i> , 2013, 2, 125-134.	1.9	25
80	Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. <i>NeuroImage: Clinical</i> , 2018, 17, 312-324.	2.7	23
81	Short-interval observational data to inform clinical trial design in Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1291-1298.	1.9	22
82	Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly. <i>Drugs and Aging</i> , 2018, 35, 959-971.	2.7	22
83	Robust Markers and Sample Sizes for Multicenter Trials of Huntington Disease. <i>Annals of Neurology</i> , 2020, 87, 751-762.	5.3	22
84	Diffusion imaging in Huntington's disease: comprehensive review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 62-69.	1.9	22
85	Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells. <i>Scientific Reports</i> , 2017, 7, 46740.	3.3	21
86	Inconsistent emotion recognition deficits across stimulus modalities in Huntington's disease. <i>Neuropsychologia</i> , 2014, 64, 99-104.	1.6	20
87	Characterizing White Matter in Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 52-60.	1.5	20
88	Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study. <i>EBioMedicine</i> , 2021, 65, 103266.	6.1	20
89	Expanding the Spectrum of Movement Disorders Associated With <i>C9orf72</i> Hexanucleotide Expansions. <i>Neurology: Genetics</i> , 2021, 7, e575.	1.9	20
90	Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease. <i>Neurology: Genetics</i> , 2021, 7, e617.	1.9	20

#	ARTICLE	IF	CITATIONS
91	Natural biological variation of white matter microstructure is accentuated in Huntington's disease. <i>Human Brain Mapping</i> , 2018, 39, 3516-3527.	3.6	19
92	Disease Onset in Huntington's Disease: When Is the Conversion?. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 352-360.	1.5	19
93	An <scp>MDS</scp> Evidence-Based Review on Treatments for Huntington's Disease. <i>Movement Disorders</i> , 2022, 37, 25-35.	3.9	19
94	Biomarker development for Huntington's disease. <i>Drug Discovery Today</i> , 2014, 19, 972-979.	6.4	18
95	Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease. <i>Human Brain Mapping</i> , 2016, 37, 4615-4628.	3.6	18
96	Structural imaging in premanifest and manifest Huntington disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2017, 144, 247-261.	1.8	18
97	Expression of mutant exon 1 huntingtin fragments in human neural stem cells and neurons causes inclusion formation and mitochondrial dysfunction. <i>FASEB Journal</i> , 2020, 34, 8139-8154.	0.5	18
98	Altered Intracortical T1-Weighted/T2-Weighted Ratio Signal in Huntington's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 805.	2.8	17
99	Relating quantitative <scp>7T MRI</scp> across cortical depths to cytoarchitectonics, gene expression and connectomics. <i>Human Brain Mapping</i> , 2021, 42, 4996-5009.	3.6	17
100	Skeletal Muscle Atrophy in R6/2 Mice - Altered Circulating Skeletal Muscle Markers and Gene Expression Profile Changes. <i>Journal of Huntington's Disease</i> , 2014, 3, 13-24.	1.9	16
101	Test-Retest Reliability of Measures Commonly Used to Measure Striatal Dysfunction across Multiple Testing Sessions: A Longitudinal Study. <i>Frontiers in Psychology</i> , 2017, 8, 2363.	2.1	16
102	Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington's disease by etanercept treatment. <i>Scientific Reports</i> , 2019, 9, 7202.	3.3	16
103	Defining pediatric huntington disease: Time to abandon the term <i>Juvenile Huntington Disease</i>?. <i>Movement Disorders</i> , 2019, 34, 584-585.	3.9	16
104	Therapeutic Antisense Targeting of Huntingtin. <i>DNA and Cell Biology</i> , 2020, 39, 154-158.	1.9	16
105	Huntington's Disease Clinical Trials Corner: April 2022. <i>Journal of Huntington's Disease</i> , 2022, 11, 105-118.	1.9	16
106	Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2012, 1, 97-106.	1.9	15
107	Large-scale brain network abnormalities in Huntington's disease revealed by structural covariance. <i>Human Brain Mapping</i> , 2016, 37, 67-80.	3.6	15
108	Mislocalization of Nucleocytoplasmic Transport Proteins in Human Huntington's Disease PSC-Derived Striatal Neurons. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 742763.	3.7	15

#	ARTICLE	IF	CITATIONS
109	Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study. <i>NeuroImage: Clinical</i> , 2018, 19, 66-70.	2.7	14
110	Quantification of huntingtin protein species in Huntington's disease patient leukocytes using optimised electrochemiluminescence immunoassays. <i>PLoS ONE</i> , 2017, 12, e0189891.	2.5	14
111	Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntington's disease. <i>Neuropsychology</i> , 2018, 32, 958-965.	1.3	13
112	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. <i>JAMA Neurology</i> , 2017, 74, 1352.	9.0	12
113	Working Memory-Related Effective Connectivity in Huntington's Disease Patients. <i>Frontiers in Neurology</i> , 2018, 9, 370.	2.4	12
114	Combined cerebral atrophy score in Huntington's disease based on atlas-based MRI volumetry: Sample size calculations for clinical trials. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 179-184.	2.2	12
115	Composite <scp>UHDRS</scp> Correlates With Progression of Imaging Biomarkers in Huntington's Disease. <i>Movement Disorders</i> , 2021, 36, 1259-1264.	3.9	12
116	Analysis of White Adipose Tissue Gene Expression Reveals CREB1 Pathway Altered in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2015, 4, 371-382.	1.9	11
117	Age of onset in Huntington's disease is influenced by CAG repeat variations in other polyglutamine disease-associated genes. <i>Brain</i> , 2017, 140, e42-e42.	7.6	11
118	Design optimization for clinical trials in early-stage manifest Huntington's disease. <i>Movement Disorders</i> , 2017, 32, 1610-1619.	3.9	11
119	Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington's Disease T Lymphocytes. <i>PLoS ONE</i> , 2015, 10, e0141793.	2.5	11
120	Imbalanced basal ganglia connectivity is associated with motor deficits and apathy in Huntington's disease. <i>Brain</i> , 2022, 145, 991-1000.	7.6	11
121	Activity or connectivity? A randomized controlled feasibility study evaluating neurofeedback training in Huntington's disease. <i>Brain Communications</i> , 2020, 2, fcaa049.	3.3	10
122	Tracking Huntington's Disease Progression Using Motor, Functional, Cognitive, and Imaging Markers. <i>Movement Disorders</i> , 2021, 36, 2282-2292.	3.9	10
123	Timing of selective basal ganglia white matter loss in premanifest Huntington's disease. <i>NeuroImage: Clinical</i> , 2022, 33, 102927.	2.7	10
124	Reference Genes Selection for Transcriptional Profiling in Blood of HD Patients and R6/2 Mice. <i>Journal of Huntington's Disease</i> , 2013, 2, 185-200.	1.9	8
125	The Potential of Composite Cognitive Scores for Tracking Progression in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2014, 3, 197-207.	1.9	8
126	Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 634.	2.0	8



#	ARTICLE	IF	CITATIONS
127	One decade ago, one decade ahead in huntington's disease. <i>Movement Disorders</i> , 2019, 34, 1434-1439.	3.9	7
128	Wild-type huntingtin regulates human macrophage function. <i>Scientific Reports</i> , 2020, 10, 17269.	3.3	7
129	Apathy Associated With Impaired Recognition of Happy Facial Expressions in Huntingtonâ€™s Disease. <i>Journal of the International Neuropsychological Society</i> , 2019, 25, 453-461.	1.8	6
130	Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance. <i>PLOS Currents</i> , 2016, 8, .	1.4	6
131	Longitudinal expression changes are weak correlates of disease progression in Huntingtonâ€™s disease. <i>Brain Communications</i> , 2020, 2, fcaa172.	3.3	6
132	Longitudinal Structural <scp>MRI</scp> in Neurologically Healthy Adults. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 1385-1399.	3.4	5
133	A new family with GLRB-related hyperekplexia showing chorea in homo- and heterozygous variant carriers. <i>Parkinsonism and Related Disorders</i> , 2020, 79, 97-99.	2.2	4
134	A small molecule kicks repeat expansion into reverse. <i>Nature Genetics</i> , 2020, 52, 136-137.	21.4	3
135	Reply to â€˜Topographical layer imaging as a tool to track neurodegenerative disease spread in M1â€™. <i>Nature Reviews Neuroscience</i> , 2021, 22, 69-69.	10.2	3
136	Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntingtonâ€™s Disease. <i>Frontiers in Neurology</i> , 2021, 12, 616272.	2.4	3
137	<scp>CAG</scp> Somatic Instability in a Huntington Disease Expansion Carrier Presenting with a Progressive Supranuclear Palsyâ€™like Phenotype. <i>Movement Disorders</i> , 2022, 37, 1555-1557.	3.9	3
138	Neurofilament light-associated connectivity in young-adult Huntingtonâ€™s disease is related to neuronal genes. <i>Brain</i> , 2022, 145, 3953-3967.	7.6	3
139	Learning Subject-Specific Directed Acyclic Graphs With Mixed Effects Structural Equation Models From Observational Data. <i>Frontiers in Genetics</i> , 2018, 9, 430.	2.3	2
140	Altered nuclear architecture in blood cells from Huntingtonâ€™s disease patients. <i>Neurological Sciences</i> , 2022, 43, 379-385.	1.9	2
141	A Multi-Study Model-Based Evaluation of the Sequence of Imaging and Clinical Biomarker Changes in Huntingtonâ€™s Disease. <i>Frontiers in Big Data</i> , 2021, 4, 662200.	2.9	2
142	J01â€™...Effects of IONIS-HTTRX (RG6042) in patients with early huntingtonâ€™s disease, results of the first htt-lowering drug trial. , 2018, , .		2
143	â€œOn Choreaâ€: 150â€™%Years of the Beginning of Hope. <i>Movement Disorders</i> , 2022, 37, 2194-2196.	3.9	2
144	Reply letter to Jinnah â€œLocus pocusâ€ and Albanese â€œComplex dystonia is not a category in the new 2013 consensus classificationâ€: Necessary evolution, no magic!. <i>Movement Disorders</i> , 2016, 31, 1760-1762.	3.9	1

#	ARTICLE	IF	CITATIONS
145	Aberrant Striatal Value Representation in Huntington's Disease Gene Carriers 25 Years Before Onset. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 910-918.	1.5	1
146	Opportunity cost determines free-operant action initiation latency and predicts apathy. <i>Psychological Medicine</i> , 2023, 53, 1850-1859.	4.5	1
147	D16â€¦White matter microstructure and natural biological variation in huntingtonâ€™s disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A39.2-A39.	1.9	0
148	K4â€¦The cost and value of a huntingtonâ€™s disease multidisciplinary team meeting. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A80.2-A80.	1.9	0
149	D21â€¦Longitudinal compensation in the cognitive network in huntingtonâ€™s disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A42.1-A42.	1.9	0
150	B48â€¦DNA repair pathways as a common genetic mechanism modulating the age at onset in polyglutamine diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A26.1-A26.	1.9	0
151	D20â€¦Operationalising compensation over time in neurodegenerative disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A41.2-A41.	1.9	0
152	D4â€¦Prediction of huntingtonâ€™s disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A35.1-A35.	1.9	0
153	D8â€¦Tms-eg markers of inhibitory deficits in huntingtonâ€™s disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A36.2-A36.	1.9	0
154	D22â€¦Compensation in preclinical huntingtonâ€™s disease: evidence from the track-on HD study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A42.2-A42.	1.9	0
155	D10â€¦Neurofilament light protein in blood predicts regional atrophy in huntingtonâ€™s disease. , 2018, , .		0
156	E11â€¦Compensation in huntingtonâ€™s disease. , 2018, , .		0
157	C01â€¦Glutamine codon usage and somatic mosaicism of the HTT cag repeat are modifiers of huntington disease severity. , 2018, , .		0
158	F45â€¦Apathy associated with impaired recognition of happy facial expressions in huntingtonâ€™s disease. , 2018, , .		0
159	Response to the letter to the editor by Reilmann et al referring to our article titled â€œMotor cortex synchronization influences the rhythm of motor performance in premanifest Huntington's diseaseâ€. <i>Movement Disorders</i> , 2018, 33, 1371-1371.	3.9	0
160	Multimodal characterization of the visual network in Huntingtonâ€™s disease gene carriers. <i>Clinical Neurophysiology</i> , 2019, 130, 2053-2059.	1.5	0
161	Automated Segmentation of Cortical Grey Matter from T1-Weighted MRI Images. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	0
162	9â€¦Aberrant striatal value representation in Huntingtonâ€™s disease gene carriers 25 years before onset. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, e4.1-e4.	1.9	0

#	ARTICLE	IF	CITATIONS
163	F05â€¦Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis. , 2021, , .		0
164	E01â€¦Modelling the trajectory of cortical atrophy in huntingtonâ€™s disease. , 2018, , .		0
165	F59â€¦Huntingtonâ€™s disease young adult study (HD-YAS). , 2018, , .		0
166	D08â€¦Neurofilament light protein in blood as a potential biomarker of neurodegeneration in huntingtonâ€™s disease: a retrospective cohort analysis. , 2018, , .		0
167	The application of NMR-based metabonomics in neurological disorders. Neurotherapeutics, 2006, 3, 358-372.	4.4	0
168	Suppression of Somatic Expansion As a Novel Therapeutic Approach for Huntington Disease and Other Repeat Expansion Disorders. , 2022, 1, 163-175.		0